France Psoriasis Drugs Market Size, Share, and COVID-19 Impact Analysis, By Class (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteroids, and Others), By Treatment (Topicals, Systemic, and Biologics), and France Psoriasis Drugs Market Insights, Industry Trend, Forecasts to 2035

France Psoriasis Drugs Market Insights Forecasts to 2035

• The France Psoriasis Drugs Market Size was Estimated at USD 971.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.93% from 2025 to 2035
• The France Psoriasis Drugs Market Size is Expected to Reach USD 2,752.1 Million by 2035

The France Psoriasis Drugs Market Size is anticipated to reach USD 2,752.1 Million by 2035, Growing at a CAGR of 9.93% from 2025 to 2035. France's Psoriasis Drug Market Size Grows steadily, driven by biologics, innovation, and increasing patient awareness.

Market Overview

The France Psoriasis Drugs Market Size encompasses the development, distribution, and sale of medications used to treat psoriasis, a chronic autoimmune condition that causes inflammation and scaling of the skin. Psoriasis can range from mild to severe and often requires long-term management. The market includes various types of treatments such as topical creams, systemic drugs, and biologic therapies that are prescribed based on disease severity and patient response. In France, a significant number of individuals are affected by this condition, contributing to a consistent need for effective therapeutic options. Treatments are typically prescribed by dermatologists and are available through pharmacies and hospitals under the supervision of healthcare professionals. Regulatory oversight by authorities like the French National Agency for Medicines and Health Products Safety (ANSM) ensures that all available treatments meet stringent safety and efficacy standards. The market continues to evolve as new therapies become available, offering more targeted approaches to managing the disease.

Report Coverage

This research report categorizes the market size for the France psoriasis drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France psoriasis drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France psoriasis drugs market.

Driving Factors

Key driving factors of the France psoriasis drugs market include the rising prevalence of psoriasis, increasing awareness about the disease, and the growing adoption of biologic therapies that offer targeted and effective treatment. Advancements in pharmaceutical research have led to the development of novel drugs with improved efficacy and fewer side effects. Additionally, strong healthcare infrastructure, favorable reimbursement policies, and support from public health campaigns contribute to increased diagnosis rates and treatment access, further fueling market growth across the country.

Restraining Factors

Restraints in the France psoriasis drugs market include the high cost of biologic treatments, limited access for patients without comprehensive insurance, and potential side effects associated with long-term drug use. Additionally, strict regulatory requirements and the availability of alternative therapies may hinder the widespread adoption of newer medications.

Market Segmentation

The France psoriasis drugs market share is classified into class and treatment.

• The tumor necrosis factor inhibitors segment held a leading revenue share in 2024 and is expected to grow at a remarkable CAGR during the forecast period.

The France psoriasis drugs market is segmented by class into tumor necrosis factor inhibitors, interleukin inhibitors, vitamin D analogues, and corticosteroids, and others. Among these, the tumor necrosis factor inhibitors segment held a leading revenue share in 2024 and is expected to grow at a remarkable CAGR during the forecast period. The segment is driven by their effectiveness in treating moderate to severe psoriasis and established clinical use. These drugs, such as etanercept and adalimumab, have demonstrated strong efficacy in reducing inflammation and skin lesions.

• The biologics segment held a major revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France psoriasis drugs market is segmented by treatment into topicals, systemic, and biologics. Among these, the biologics segment held a major revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The dominance is attributed to the superior efficacy of biologics in managing moderate to severe psoriasis, especially in patients who do not respond well to conventional treatments. Biologics target specific components of the immune system, offering more precise and sustained relief with fewer side effects.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France psoriasis drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novartis AG
• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Eli Lilly and Company
• Laboratoires Pierre Fabre
• Laboratoires Expanscience
• Ipsen
• Galderma
• Almirall, S.A.
• Others

Recent Developments:

• In May 2025, Sandoz launched Pyzchiva, the first ustekinumab biosimilar in Europe, including France. It's approved for treating plaque psoriasis, psoriatic arthritis, and Crohn’s disease in adults, and pediatric plaque psoriasis in patients over 60 kg.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France psoriasis drugs market based on the below-mentioned segments:

France Psoriasis Drugs Market, By Class

• Tumor Necrosis Factor Inhibitors
• Interleukin Inhibitors
• Vitamin D Analogues
• Corticosteroids
• Others

France Psoriasis Drugs Market, By Treatment

• Topicals
• Systemic
• Biologics